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1. Introduction
Embryonic stem (ES) cells isolated from the inner cell mass (ICM) of blastocysts possess
the defining pluroptency: unlimited self-renewal and giving rise to all cells of the organ‐
ism[1, 2]. Thus, ES cells hold great promise for regenerative medicine to treat many dis‐
eases including heart failure,  diabetes,  Alzheimer’s and Parkinson’s disease by replacing
the damaged cells with ES cell-derived healthy ones. The recent advent of induced pluri‐
potent stem (iPS) cells reprogrammed from somatic cells has the potential to revolution‐
ize  the  field  of  regenerative  medicine  since  patient-derived  iPS  cells,  in  principle,
circumvent  the  ethical  problems  and  immune  rejection  associated  with  human  ES
cells[3]. Nevertheless, the future clinical translation of ES cells and iPS cells is facing nu‐
merous hurdles. Understanding the molecular mechanisms that impart ES cells with plu‐
ripotency  may  help  address  some  of  these  challenges.  The  past  few  years  have  seen
tremendous progress in understanding of  mechanisms which govern ES cell  pluripoten‐
cy.  In  this  chapter,  we  will  review  critical  signaling  and  transcription  factor  networks
that have been identified to maintain ES cell pluripotency.
2. Signaling pathways of ES cells
ES cells require extrinsic growth factors to maintain their pluripotency in culture.  These
extrinsic  growth  factors  act  on  different  signaling  pathways  to  regulate  intrinsic  tran‐
scription factor  networks  to  sustain  ES  cells  in  the  undifferentiated state.  The  signaling
pathways  required to  support  pluripotency in  mouse  ES  cell  are  distinct  from those  in
human ES cells (Figure 1).
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Figure 1. Exogenous growth factors signal through distinct signaling pathways to regulate transcription factors for ES
cell pluripotency.
2.1. LIF/JAK/STAT3 pathway
Mouse ES cells were originally cultured on feeder layers derived from mouse embryonic fi‐
broblasts (MEF). Later it was found that Leukaemia Inhibitory Factor (LIF), a member of the
Interleukin-6 cytokines produced by MEFs, was the key factor to maintain pluripotency of
mouse ES cells by inhibiting their differentiation[4]. Upon LIF binding, the LIF receptor re‐
cruits gp130 to form a heterodimer which subsequently activates Janus kinase (JAK)
through transphosphorylation[5]. Activated JAK then phosphorylate gp130, creating a dock‐
ing site to bind the SH2 domain of Signal Transducers and Activators of Transcription 3
(STAT3)[6-9]. Once STAT3 binds to the gp130 docking site, JAK then phosphorylates the re‐
cruited STAT3. Phosphorylated STAT3 forms a homodimer, which subsequently translocate
into the nucleus, where it binds to gene enhancers to regulate target gene expression[10-12].
Although the LIF/JAK/STAT3 pathway has been well documented to maintain pluripotency
of mouse ES cells in the presence of serum, the mechanisms by which activated STAT3 func‐
tions in this regard is poorly understood. Recently, studies in identification of STAT3 target
genes have improved our understanding of activated STAT3 in maintaining pluripotency.
Chen et al identified 718 STAT3-bound genomic sites that were co-occupied by pluripotency
transcription markers (Oct4, Sox2 and Nanog) by using chromatin immunoprecipitation se‐
quencing (ChIP-seq)[12]. In addition, Kidder and colleagues found that STAT3 target genes
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enriched in ES cells were downregulated in differentiated cells by mapping STAT3 binding
targets in mouse ES cells and differentiated embryoid bodies (EBs)[13]. Along with these re‐
sults, it has been demonstrated that knocking down STAT3-target genes induces activation
of endodermal and mesodermal genes, supporting the conclusion that STAT3 prevents
mESC differentiation by suppressing lineage-specific genes[14].
Interestingly,  the LIF receptor and gp130 are also expressed in human ES cells  and hu‐
man LIF can induce STAT3 phosphorylation and nuclear translocation in human ES cells.
However, human LIF is unable to maintain the pluripotent state of human ESs, suggest‐
ing  that  mouse  and  human  ES  cells  require  distinct  signaling  mechanisms  to  govern
their pluripotency[15].
2.2. TGF-β signaling
TGF-β superfamily consists of more than 40 members, including TGF-β, Activin, Nodal, and
bone morphogenetic proteins (BMPs). The TGF-β members transduce signals by binding to
heteromeric complexes of serine/threonine kinase receptors, type I and type II receptors,
which subsequently activate intracellular Smad proteins. Smads 2 and 3 are specifically acti‐
vated by activin, nodal and TGF-β ligands, whereas Smads 1, 5 and 8 are activated by BMP
ligands[16, 17] (Figure 1). The TGF-β-related signaling pathways play complex roles in regu‐
lating the pluripotency and cell fate of ES cells.
2.2.1. BMP signaling pathway
Bone Morphogenetic Protein (BMP) is a subset of the TGF-β superfamily[18]. When BMP li‐
gands bind to type II BMP receptors (BMPRII), BMPRII then recruits and phosphorylates
type I BMP receptors (BMPRI). Activated type I receptors subsequently phosphorylate BMP-
responsive SMAD1/5/8 which then forms a complex with SMAD4 and translocates into nu‐
cleus to regulate target gene expression (Figure 1). In mouse ES cells, LIF can substitute MEF
feeder layers in maintaining pluripotency in the presence of animal serum by activating the
transcription factor STAT3. However, in serum-free cultures, LIF is insufficient to block neu‐
ral differentiation and maintain pluripotency. Recently, Ying et al reported that BMP was
able to replace serum to maintain pluripotency of mouse ES cells in the presence of LIF.
BMP has been shown to phosphorylate SMAD1/5 and activate inhibitors of differentiation
(Id) genes, which block neural differentiation by antagonizing neurogenic transcription fac‐
tors[19]. In the absence of MEF and serum, exogenous LIF, in combination with BMP4 pro‐
teins, can sufficiently maintain the pluripotency of mouse ES cells derived from
“permissive” mouse strains.
In contrast to a maintenance role in mouse ES cell pluripotency, BMP has been shown to
promote human ES cells differentiation to trophoblasts, and inhibiting BMP signaling with
the BMP antagonist, Noggin, sustains the undifferentiated state of human ES cells[20, 21]. In
consistence, dorsomorphin and DMH1, small molecule BMP inhibitors previously identified
in our lab, were shown to promote long-term self-renewal an pluripotency of human ES
cells, presumably by inhibiting BMP induced extraembryonic lineage differentiation[22-25].
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2.2.2. TGF-β/activin/nodal signaling pathway
Although MEFs feeder layers were initially used to co-culture both mouse and human ES
cells, signal factors secreted from MEFs to maintain pluripotency of the two types of ES cells
are fundamentally different. Sato et al first discoveried that TGF-β and Nodal genes were
highly expressed in undifferentiated human ES cells[26]. Beattie et al later reported that Ac‐
tivin A, a member of the TGF-β superfamily, was secreted by MEFs, and medium enriched
with activin A can replace MEF feeder-layers or MEF-conditioned media to maintain human
ES cells in an undifferentiated state[27]. In consistence, James et al demonstrated that the
TGF-β/Activin/Nodal pathway was activated through the transcription factors Smad2/3 in
undifferentiated human ES cells[28]. The notion that TGF-β/Activin/Nodal signaling sup‐
ports human ES self-renewal and pluripotency is further supported by the fact that recombi‐
nant Activin or Nodal stimulation induces higher levels of pluripotent protein expression
(Oct4 and Nanog), while inhibition of TGF-β/Activin/Nodal signaling with Lefty or Follista‐
tin decreases expression of these pluripotent proteins in human ES cells[29, 30].
Recent studies have focused on understanding the molecular mechanisms of TGF-β/Activin/
Nodal signaling in retaining human ES cells pluripotency. Xu and colleagues showed that
TGF-β/Activin/Nodal signaling activated Smad2/3 which subsequently binds to the Nanog
promoter in undifferentiated human ES cells to induce expression of Nanog, a pluripotent
transcription factor[31]. Additionally, mutating the putative Smad-binding sites reduced the
response of Nanog to modulation of TGF-β signaling[31]. Nanog was also shown to coordi‐
nate with Smad2 in a negative-feedback loop to inhibit human ES cell differentiation[32]. In
contrast to its important role in maintaining human ES cell pluripotency, the TGF-β/Activin/
Nodal signaling is not essential for pluripotency of mouse ES cells. Although this pathway
was shown to be active in undifferentiated mouse ES cells as assessed by phosphorylation of
smad 2/3, inhibition of smad 2/3 phosphorylation by SB431542 had no effect on the undiffer‐
entiated state of mouse ES cells[28]. However, the TGF-β/Activin/Nodal signaling may play
a role in mouse ES proliferation. A recent study showed that Inhibition of TGF-β/Activin/
Nodal signaling by Smad7 or SB-431542 dramatically decreased mouse ES cell proliferation
without effect on their pluripotency[33].
2.2.3. Growth and Differentiation factor 3 (GDF-3)
GDF-3 is another TGF-beta superfamily member that plays opposite roles in mouse and
human ES cells.  GDF-3,  which acts as a BMP antagonist  by direct  binding to BMP-4,  is
specifically expressed in the pluripotent state of both mouse and human ES cells[34]. Ec‐
topic  expression of  GDF-3 leads to  the  maintenance of  pluripotency in  human ES cells,
whereas a similar effect is observed in mouse ES cells when GDF-3 levels are decreased.
In the absence of LIF, GDF-3-deficient mouse ES cells can still  sustain pluripotent mark‐
ers[34].  These  results  are  consistent  with  previously  discussed  BMP  signals  which  can
promote  pluripotency  of  mouse  ES  cells,  but  cause  differentiation  of  human  ES  cells.
Thus lower concentrations of BMP antagonists, such as GDF-3, may enhance pluripoten‐
cy in mouse ES cells,  whereas higher levels of GDF-3 may favor pluripotency of human
ES cells by abrogating BMP signaling.
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2.3. FGF/MEK signaling
The importance of  Fibroblast  growth factor (FGF) signaling for human ES cells  pluripo‐
tency  is  highlighted  by  the  facts  that  human  ES  cells  are  traditionally  cultured  in  the
presence of Fibroblast growth factors (FGFs) either on fibroblast feeder layers or in fibro‐
blast-conditioned medium[35, 36]. Studies have demonstrated that all four FGF receptors
(FGFR1, FGFR3 and FGFR4) and several components (SOS1, PTPN11 and RAF1) of their
downstream  activation  cascade  are  significantly  upregulated  in  undifferentiated  human
ES cells, in comparison to differentiated human ES cells[37-39]. In consistence, withdraw‐
al  of  FGFs or  inhibition of  FGF signaling by a FGFR inhibitor,  SU5402,  rapidly induces
human ES cell differentiation[40-42].
Although the pluirpotency maintenance role of exogenous FGFs in human ES cell has been
known for a long time, the molecular mechanisms by which they function remain unclear.
FGFs signal by binding to FGF receptors (FGFRs), and activate multiple signaling cascades,
including Mitogen-Activated Protein Kinases (MAPKs), the Janus kinase/signal transducer
and activator of transcription (Jak/Stat), phosphatidylinositol 3-kinase (PI3K) and phosphoi‐
nositide phospholipase C (PLCg) pathway[43]. Several studies have highlighted the FGF
contribution to the maintenance of human ES cells mainly through the FGF/MEK pathway
(Figure 1), [44, 45]. Studies have showed that FGF2 induces feeder layer cells to secret
TGFβ1 and insulin-like growth factor 2 (IGF2), which can subsequently promote the undif‐
ferentiated state of human ES cells[46, 47]. Bendall et al further reported that the function of
exogenous FGFs in promoting ES self-renewal could be replaced by addition of IGF2 alone,
suggesting an indirect role of FGFs for human ES cell growth. However, this model was
challenged in subsequent publications from Wang et al who reported that exogenous IGF2
alone was insufficient to maintain undifferentiated growth of human ES cells, and they pro‐
posed that FGFs may play a direct role in blocking caspase-activated apoptosis through
anoikis in human ES cells[48]. Recently, Eiselleova and colleagues postulated a new model
whereby endogenous FGF-2 signaling maintained the undifferentiated state and survival of
human ESCs, while exogenous FGF-2 mainly suppress cell death and apoptosis genes, thus
indirectly contributing to the maintenance of human ES cell pluripotency[49].
FGF signaling in mouse ES cells has also been extensively investigated. Mouse ES cells geneti‐
cally deficient in Fgf4 and extracellular-signal regulated kinase 2 (Erk2) differentiate ineffi‐
ciently. These results can be reproduced using inhibitors of FGF receptor and ERK, suggesting
blockage of the FGF/MEK signaling pathway promotes mouse ES cell pluripotency[50-52]. In‐
deed, serum-free mouse ES cell medium supplemented with FGF/MEK inhibitors and LIF per‐
mits  the  derivation  of  mouse  ES  cells  in  the  absence  of  feeders  from  strains  normally
considered non-permissive[53]. In addition, a recently identified compound, Pluripotin/SC1,
has been shown to maintain mouse ES pluripotency by inhibiting ERK1 and activating the pho‐
phoinositide-3 kinase (PI3K) pathway through blocking RasGAP[54-56] [57, 58]. Although in‐
hibition of FGF/MEK pathway can attenuate ES cell differentiation, it is insufficient to support
mouse ES cell self-renewal. Combination of the MEK inhibitor PD0325901 with the Glycogen
synthase kinase-3 (GSK-3) inhibitor CHIR99021 (known as 2i) can efficiently sustain the pluri‐
potency of mouse ES cells in the absence of exogenous cytokines[59, 60]. Several groups dem‐
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onstrated that improvement of mouse ES cell pluripotency by inhibition of GSK-3 occurred via
Wnt/β-catenin signaling, whereas many others argued that GSK3 was likely to exert β-catenin
independent effects in ES cells[59, 61-67].
As demonstrated above, human and mouse ES cells are both derived from blastocyst-stage
embryos, but they require different biological signals for maintaining pluripotency. In gen‐
eral, mouse ES cells maintain their pluripotency by activating LIF/STAT3 and BMP signal‐
ing, while human ES cells require TGF-β/Nodal and FGF/MEK pathways. Interestingly,
several pathways, such as BMP and FGF/MEK, have completely oppositing effects on main‐
taining the pluriotency of mouse and human ES cells. Activation of BMP signaling and in‐
hibition of the FGF/MEK pathway promote mouse ES self-renewal, whereas inhibition of
BMP signaling and activation of FGF/MEK pathway sustain human ES cell pluripotency.
These distinct signaling effects on pluripotency may reflect intrinsic differences between
mouse and human ES cells. Recent studies have demonstrated that conventional human ES
cells do not represent the “ground or naïve state” of stemness, but rather a more develop‐
mentally mature “primed state” resembling mouse epiblast stem cells (mEpiSCs) found in
the post-implantation, pre-gastrulation stage of embryos [68-74]. Conventional human ES
cells exhibit numerous similarities to the mouse EpiSCs over mouse ES cells (Table 1). For
instance, conventional human ES cells and mouse EpiSCs display flattened cell colonies and
epigenetic X-chromosome inactivation (XiXa), and require Activin and FGF for pluripotency
maintanince. In contrast, mouse ES cells exhibit dome-shaped colony morphology and epi‐
genetic activation of both X-chromosome (XaXa), and require LIF/STAT3 signaling to pro‐
mote self-renewal. Subsequent studies have demonstrated that the medium containing “2i”
(MEK inhibitor and GSK-3 inhibitor), when supplemented with other factors (such as for‐
skolin), can efficiently convert conventional human ES cells into a ground or “naïve” state
with display of hallmark features of mouse ES cells. This medium can also maintain human
ES cell pluriptoency at the naïve state [69, 70, 72, 75-78].
Table 1. Comparison of the properties of mouse ES cells (mESCs), mouse epiblast stem cells (mEpiSCs), human ES cells
(hESCs) and human iPS cells (hiPSCs).
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3. The regulatory network of pluripotency factors
ES cell pluripotency is conferred by a unique transcriptional network[79]. Early global tran‐
scriptional profiles and genetic studies have identified several critical transcription factors
that are required for the pluripotency of ES cells, such as Oct4, Sox2, Nanog, Foxd3 and Id,
etc [80-88]. Here we will mainly focus on Oct4, Sox2 and Nanog, three key transcription fac‐
tors of the core pluripotency transcriptional network.
3.1. OCT4 and SOX2
OCT4 (also known as Oct3), a POU domain-containing transcription factor, was one of the
first transcription factors identified as essential for both early embryo development and plu‐
ripotency maintenance in ES cells[84, 89]. The expression of Oct4 is activated at the 8-cell
stage and is later restricted to the inner cell mass (ICM) and germ cells in early mouse em‐
bryogenesis in vivo [89-92]. Oct4 is highly expressed in both human and mouse ES cells, and
its expression diminishes when these cells differentiate and lose pluripotency. Oct4 regu‐
lates a broad range of target genes including Fgf4, Utf1, Opn, Rex1/ Zfp42, Fbx15, Sox2 and
Cdx2[93-95]. Repression of Oct4 activity in ES cells upregulates Cdx2 expression, leading to
ES cell differentiation into trophectoderm[96]. Oct4 is also known to activate downstream
genes by binding to enhancers carrying the octamer–sox motif (Oct–Sox enhancer), for syn‐
ergistic activation with Sox2. In contrast with its target genes, little is known about Oct4 up‐
stream regulators. The Oct4 promoter contains conserved distal and proximal enhancers
that can either repress or activate its expression depending on the binding factors occupying
these sites[97, 98]. The precise level of Oct4 is important for ES cell fate determination. Loss
of Oct4 causes inappropriate differentiation of ES cells into trophectoderm, whereas overex‐
pression of Oct4 results in differentiation into primitive endoderm and mesoderm[99, 100].
Sox2 is an HMG-box transcription factor that is detected in pluripotent cell lineages and the
nervous system[101-103]. Inactivate Sox2 in vivo results in early embryonic lethality due to
the failure of ICM maintenance[102]. Sox2 can form a complex with the Oct4 protein to occu‐
py Oct–Sox enhancers to regulate target gene expression. Oct–Sox enhancers are found in
the regulatory region of most of the genes that are specifically expressed in pluripotent stem
cells, such as Oct4, Sox2, Nanog, Utf1, Lefty, Fgf4 and Fbx15[93, 94, 104-108].
3.2. Nanog
Nanog is another homeobox-containing transcription factor that is specifically expressed in
pluripotent ES cells. The essential role of Nanog in maintaining the pluripotency of ES cells
is highlighted by the facts that Nanog-deficient ES cells are prone to differentiation, whereas
forced expression of Nanog partially renders ES cells self-renewal potential in the absence of
LIF[85, 86, 109]. How Nanog regulates stem cell pluripotency remains entirely unknown.
Studies have indicated that Nanog may maintain ES cell pluripotency by 1) downregulating
downstream genes essential for cell differentiation such as Gata4 and Gata6 and 2) activat‐
ing the expression of genes necessary for self-renewal such as Rex1 and Id[19, 85, 86]. Al‐
though it is widely accepted that Nanog, like Oct4 and Sox2, play a central role in
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pluripotency maintenance, this dogma has been challenged by a subsequent report that
Nanog protein levels are undetectable in a fraction of ES cells that express Oct4, and the
pure populations of Nanog−/− ES cells can be propagated without losing expression of other
pluripotency markers[110].
Little is known about the mechanism by which Nanog is regulated in ES cells. Recently, Su‐
zuki et al showed that Nanog expression was upregulated by BrachyuryT and STAT3 in
mouse ES cells[111]. In human ES cells and in mouse EpiSCs, Vallier et al reported that Acti‐
vin/Nodal signaling stimulated expression of Nanog, which in turn prevents FGF-induced
neuroectoderm differentiation [112]. In addition, several studies indicated that the Oct4/
Sox2 complex was directly bound to the Nanog promoter to regulate target gene expression
[106, 107, 113]. Genomic studies have revealed that Oct4, Sox2, and Nanog frequently bind
the same regulatory regions in undifferentiated mouse and human ESCs, and that these
binding sites are often in close proximity to one another[113-116]. These results indicate that
Oct4, Sox2, and Nanog may physically interact with each other and coordinately regulate
target genes in some cases. Additionally, Goke and colleagues reported that combinatorial
binding sites of the Oct4/Sox2/Nanog were more conserved between mouse and human ES
cells than individual binding sites were [113, 114, 117-119].
4. Summary
Understanding the molecular mechanism of pluripotency can greatly expand our knowl‐
edge of ES cell biology and facilitate future stem cell clinical applications. In the past few
years, we have seen tremendous advances in understanding ES cell pluripotency. Although
mouse ES cells and conventional human ES cells require distinct signaling pathways to
maintain pluripotency, they display similar gene expression profiles, activities of transcrip‐
tion factors (such as Oct4, Nanog and Sox2) and transcription factor networks. Our under‐
standing of pluripotency has been further expanded by the advent of iPS cells and the very
recent discovery that conventional human ES cells are more equivalent to mouse EpiSCs,
but rather “naïve state” of mouse ES cells. Nevertheless, our knowledge of the molecular
mechanisms of ES cell pluripotency is still very limited. For instance, it remains unknown
how growth factors establish and control transcriptional networks to regulate pluripoency
and how ES cells respond so precisely to exogenous cues. Given the rapid advance in ES cell
biology, we anticipate the molecular mechanisms underlying pluripotency of ES cells will
soon be uncovered and pluripotent stem cells, such as ES cells and iPS cells, will be widely
used for clinical applications in the near future.
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